Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Aafke H. Honkoop"'
Autor:
Mette S. van Ramshorst, Aafke H. Honkoop, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Caroline M.P.W. Mandigers, Sabine C. Linn, Agnes J. van de Wouw, Gabe S. Sonke, I.A.M. Mandjes, Erik van Werkhoven, Anna van der Voort, Jelle Wesseling, Inge Kemper, Laurence J. C. van Warmerdam, Lidwine W. Tick, Irma M. Oving
Publikováno v:
The Lancet Oncology. 19:1630-1640
Summary Background The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared wi
Autor:
Aafke H. Honkoop, Marie-Jeanne T. F. D. Vrancken Peeters, I.A.M. Mandjes, Caroline M.P.W. Mandigers, Irma M. Oving, Annelie J. Vulink, Lidwine W. Tick, Anna van der Voort, Inge Kemper, GS Sonke, Sabine C. Linn, Agnes J. van de Wouw, Mette S. van Ramshorst, Laurence J. C. van Warmerdam, Erik van Werkhoven, Jelle Wesseling
Publikováno v:
JAMA Oncology. 7:978
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete response rates after neoadjuvant chemotherapy with or without anthracyclines plus dualERBB2(formerlyHER2) blockade. Objective To evaluate 3-year event-free survival (EFS
Autor:
Sabine C. Linn, Gabe S. Sonke, I.A.M. Mandjes, Inge Kemper, Carolien H. Smorenburg, Aafke H. Honkoop, Erik van Werkhoven, Jacqueline M. Stouthard, Irma M. Oving, Mette S. van Ramshorst, Vincent O. Dezentjé
Publikováno v:
The Breast. 29:153-159
Background The addition of pertuzumab to neoadjuvant trastuzumab-based chemotherapy improves pathologic complete response rates in HER2-positive breast cancer. However, increased toxicity has been reported with the addition of pertuzumab, and this ma
Autor:
Hiltje de Graaf, Aafke H. Honkoop, Joan B. Heijns, Paul Hamberg, Steffen M de Groot, Agnes Jager, Stefan Sleijfer, Johanneke E.A. Portielje, Sabine C. Linn, Judith R. Kroep, Jan C. Drooger, Albert J. ten Tije, Frans L. G. Erdkamp, Harm van Tinteren, Quirine C. van Rossum-Schornagel, A. Elise van Leeuwen-Stok, Alex L. T. Imholz
Publikováno v:
Cancer. 122:2961-2970
textabstractBACKGROUND: To explore the role of bevacizumab and a chemotherapy-free approach, the authors evaluated the combination of bevacizumab, trastuzumab, and paclitaxel (HAT) and the regimen of trastuzumab and bevacizumab (HA) with the addition
Autor:
Agnes Jager, Joan B. Heijns, Aafke H. Honkoop, Jan C. Drooger, A. Elise van Leeuwen-Stok, Sabine C. Linn, Steffen M de Groot, Judith R. Kroep, Johanneke E.A. Portielje, Frans L. G. Erdkamp, Stefan Sleijfer, Albert J. ten Tije, Paul Hamberg, Harm van Tinteren, Hiltje de Graaf
Publikováno v:
Cancer Research. 75:P4-15
Background Until recently, trastuzumab (H) combined with a taxane was standard first line systemic therapy for patients with Her2 positive metastatic breast cancer (MBC) who are not candidates for endocrine therapy. Clinical studies have shown that b
Autor:
Carolien H. Smorenburg, Annette W.G. van der Velden, Elisabeth G.E. de Vries, Aafke H. Honkoop, Annelies H. Boekhout, Ido P. Kema, Bojana Milojkovic Kerklaan, Agnes J. van der Wouw, Jan H.M. Schellens, Erik van Werkhoven, Peter Nieboer, Caroline M.P.W. Mandigers, Maartje Los, Petronella B. Ottevanger, Lonneke Kessels, Dirk J. van Veldhuisen, Renske Altena, Tineke J. Smilde, Willem M. Smit, Jourik A. Gietema, Jaap de Boer
Publikováno v:
Jama Oncology, 2, 1030-7
Jama Oncology, 2, 8, pp. 1030-7
JAMA oncology, 2(8), 1030-1037. AMER MEDICAL ASSOC
Jama Oncology, 2, 8, pp. 1030-7
JAMA oncology, 2(8), 1030-1037. AMER MEDICAL ASSOC
Item does not contain fulltext IMPORTANCE: This is the first randomized placebo-controlled evaluation of a medical intervention for the prevention of trastuzumab-related cardiotoxic effects. OBJECTIVE: To determine as the primary end point whether an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2711005b972b1ee32911914e7a69418
http://hdl.handle.net/2066/171393
http://hdl.handle.net/2066/171393
Autor:
Lidwine W. Tick, Gabe S. Sonke, Jelle Wesseling, Sabine C. Linn, Aafke H. Honkoop, Irma M. Oving, I.A.M. Mandjes, Inge Kemper, Caroline M.P.W. Mandigers, Erik van Werkhoven, Vincent O. Dezentjé, Marie-Jeanne T. F. D. Vrancken Peeters, Mette S. van Ramshorst, Agnes W Van de Wouw
Publikováno v:
Journal of Clinical Oncology. 35:507-507
507 Background: Neoadjuvant chemotherapy with dual HER2 blockade boosts pathologic complete response (pCR) rates in HER2+ breast cancer. The optimal chemotherapy backbone in this setting is unknown. We conducted a multicenter phase III trial to study